A carregar...
Emerging options for the treatment of melanoma – focus on ipilimumab
Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody. It has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for use in advanced melanoma following clear evidence of survival benefit in randomized...
Na minha lista:
| Publicado no: | Immunotargets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918235/ https://ncbi.nlm.nih.gov/pubmed/27482517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S43522 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|